Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Lincoff and colleagues1 reported that patients who received bivalirudin
with provisional glycoprotein IIb/IIIa (Gp IIb/IIIa) blockade after percutaneous
coronary intervention (PCI) had a risk of acute ischemic events similar to
that of those who received heparin plus planned Gp IIb/IIIa blockade. They
also reported that bivalirudin was associated with less bleeding. We have
2 concerns, however, about the generalizability of these results.
Sharma S, Nyitray W, Bhambi B. Glycoprotein IIb/IIIa Inhibition in Percutaneous Coronary Interventions—Reply. JAMA. 2003;290(11):1451. doi:10.1001/jama.290.11.1451-a